What is Avisa Diagnostics Inc?
operates a clinical-stage medical device company.
FOGCF · Verdict
Moderate reward · elevated risk
FOGCF's standout is volatility; cash flow and balance sheet weigh on the picture.
Based on 88% data coverage
FOGCF · Verdict
Top decile vs peers
-163% free-cash-flow margin
Current ratio 0.23
-258% net margin · -289% ROE
Earnings +151.7% CAGR
Model-based scoring. For information only — not financial advice.
operates a clinical-stage medical device company. It is developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 50.00.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.